SPD 557

Drug Profile

SPD 557

Alternative Names: M-0003; SHP-557; SPD-557; SSP-002358

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Janssen Pharmaceutica; Ortho-McNeil Pharmaceutical
  • Developer Movetis; Shire-Movetis NV
  • Class Gastrokinetics
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic gastroparesis; Gastro-oesophageal reflux; Gastroparesis

Most Recent Events

  • 30 Jun 2013 Discontinued - Phase-II for Gastro-oesophageal reflux in Belgium (PO)
  • 30 Jun 2013 Discontinued - Phase-II for Gastro-oesophageal reflux in Czech Republic (PO)
  • 30 Jun 2013 Discontinued - Phase-II for Gastro-oesophageal reflux in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top